nach oben

Current Hypertension Reports

Erschienen in:

01.08.2010

Mineralocorticoid Receptor Antagonists and the Metabolic Syndrome

verfasst von: Amir Tirosh, Rajesh Garg, Gail K. Adler

Erschienen in: Current Hypertension Reports | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Key components of the metabolic syndrome (MetS), ie, obesity and insulin resistance, are associated with increased aldosterone production and mineralocorticoid receptor (MR) activation. Both MetS and hyperaldosteronism are proinflammatory and pro-oxidative states associated with cardiovascular disease. This review discusses emerging data that MR activation may contribute to abnormalities seen in MetS. In view of these data, MR antagonists may be beneficial in MetS, not only by controlling hypertension but also by reversing inflammation, oxidative stress, and defective insulin signaling at the cellular-molecular level. Clinical trials have demonstrated benefits of MR antagonists in heart failure, hypertension, and diabetic nephropathy, but additional trials are needed to demonstrate the clinical significance of MR blockade in MetS.

McNeill AM, Rosamond WD, Girman CJ, et al.: The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities study. Diabetes Care 2005, 28:385–390.CrossRefPubMed

Chen J, Muntner P, Hamm LL, et al.: The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004, 140:167–174.PubMed

Wilson PW, D’Agostino RB, Parise H, et al.: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112:3066–3072.CrossRefPubMed

Wang J, Sarnola K, Ruotsalainen S, et al.: The metabolic syndrome predicts incident congestive heart failure: a 20-year follow-up study of elderly Finns. Atherosclerosis 2010, 210:237–242.CrossRefPubMed

Wang J, Ruotsalainen S, Moilanen L, et al.: The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J 2007, 28:857–864.CrossRefPubMed

Wannamethee SG, Shaper AG, Lennon L, Morris RW: Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005, 165:2644–2650.CrossRefPubMed

Odermatt A, Atanasov AG: Mineralocorticoid receptors: emerging complexity and functional diversity. Steroids 2009, 74:163–171.CrossRefPubMed

Grossmann C, Gekle M: New aspects of rapid aldosterone signaling. Mol Cell Endocrinol 2009, 308:53–62.CrossRefPubMed

Gaddam KK, Pimenta E, Husain S, Calhoun DA: Aldosterone and cardiovascular disease. Curr Probl Cardiol 2009, 34:51–84.CrossRefPubMed

10.

Brown NJ: Aldosterone and vascular inflammation. Hypertension 2008, 51:161–167.CrossRefPubMed

11.

Funder JW: Reconsidering the roles of the mineralocorticoid receptor. Hypertension 2009, 53:286–290.CrossRefPubMed

12.

Leopold JA, Dam A, Maron BA, et al.: Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007, 13:189–197.CrossRefPubMed

13.

Shibata S, Nagase M, Yoshida S, et al.: Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008, 14:1370–1376.CrossRefPubMed

14.

Lemarie CA, Simeone SM, Nikonova A, et al.: Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res 2009, 105:852–859.CrossRefPubMed

15.

Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709–717.CrossRefPubMed

16.

Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309–1321.CrossRefPubMed

17.

Edwards NC, Steeds RP, Stewart PM, et al.: Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009, 54:505–512.CrossRefPubMed

18.

Pitt B, Reichek N, Willenbrock R, et al.: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003, 108:1831–1838.CrossRefPubMed

19.

Mehdi UF, Adams-Huet B, Raskin P, et al.: Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009, 20:2641–2650.CrossRefPubMed

20.

Bentley-Lewis R, Adler G, Perlstein T, et al.: Body Mass Index Predicts Aldosterone Production in Normotensive Adults on a High-Salt Diet. J Clin Endocrinol Metab 2007, 92:4472–4475.CrossRefPubMed

21.

Caprio M, Feve B, Claes A, et al.: Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007, 21:2185–2194.CrossRefPubMed

22.

Lamounier-Zepter V, Ehrhart-Bornstein M, Bornstein SR: Mineralocorticoid-stimulating activity of adipose tissue. Best Pract Res Clin Endocrinol Metab 2005, 19:567–575.CrossRefPubMed

23.

Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al.: Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 2003, 100:14211–14216.CrossRefPubMed

24.

Goodfriend TL, Egan BM, Kelley DE: Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids 1999, 60:401–405.CrossRefPubMed

25.

Engeli S, Bohnke J, Gorzelniak K, et al.: Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005, 45:356–362.CrossRefPubMed

26.

Ferrannini E, Seghieri G, Muscelli E: Insulin and the renin-angiotensin-aldosterone system: influence of ACE inhibition. J Cardiovasc Pharmacol 1994, 24(Suppl 3):S61–S69.PubMed

27.

Pierluissi J, Navas FO, Ashcroft SJ: Effect of adrenal steroids on insulin release from cultured rat islets of Langerhans. Diabetologia 1986, 29:119–121.CrossRefPubMed

28.

Matrozova J, Steichen O, Amar L, et al.: Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension 2009, 53:605–610.CrossRefPubMed

29.

Catena C, Colussi G, Di Fabio A, et al.: Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. Horm Metab Res 2010 Jan 29 (Epub ahead of print).

30.

Giacchetti G, Sechi LA, Rilli S, Carey RM: The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 2005, 16:120–126.CrossRefPubMed

31.

Catena C, Lapenna R, Baroselli S, et al.: Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006, 91:3457–3463.CrossRefPubMed

32.

• Fallo F, Della Mea P, Sonino N, et al.: Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens 2007, 20:855–861. Patients with primary aldosteronism had more insulin resistance (higher HOMA index) and lower levels of adiponectin than patients with low-renin essential hypertension in the absence of MetS.CrossRefPubMed

33.

Sindelka G, Widimsky J, Haas T, et al.: Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment. Exp Clin Endocrinol Diabetes 2000, 108:21–25.PubMed

34.

•• Garg R, Hurwitz S, Williams GH, et al.: Aldosterone production and insulin resistance in healthy adults. J Clin Endocrinol Metab 2010, 95:1986–1990. In normotensive healthy adults, high angiotensin II–stimulated aldosterone level was an independent predictor of insulin resistance even after adjusting for age, body mass index, and diastolic blood pressure.CrossRefPubMed

35.

Freel EM, Tsorlalis IK, Lewsey JD, et al.: Aldosterone status associated with insulin resistance in patients with heart failure—data from the ALOFT study. Heart 2009, 95:1920–1924.CrossRefPubMed

36.

Selvaraj J, Muthusamy T, Srinivasan C, Balasubramanian K: Impact of excess aldosterone on glucose homeostasis in adult male rat. Clin Chim Acta 2009, 407:51–57.CrossRefPubMed

37.

Ndisang JF, Lane N, Jadhav A: The heme oxygenase system abates hyperglycemia in Zucker diabetic fatty rats by potentiating insulin-sensitizing pathways. Endocrinology 2009, 150:2098–2108.CrossRefPubMed

38.

•• Guo C, Ricchiuti V, Lian BQ, et al.: Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008, 117:2253–2261. In obese, db/db mice, MR blockade reduced circulating triglyceride levels, decreased adipose tissue expression of inflammatory cytokines, and increased expression of adiponectin and PPARγ. In 3 T3-L1 preadipocytes, aldosterone increased expression of inflammatory cytokines and decreased expression of adiponectin and PPARγ, supporting a direct effect of aldosterone on gene expression.CrossRefPubMed

39.

•• Hirata A, Maeda N, Hiuge A, et al.: Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009, 84:164–172. In obese, db/db and ob/ob mice, MR blockade reduced insulin resistance and improved adipose tissue inflammation (decreased reactive oxygen species and macrophage infiltration). In 3 T3-L1 adipocytes, aldosterone increased intracellular reactive oxygen species.CrossRefPubMed

40.

Calle C, Campion J, Garcia-Arencibia M, et al.: Transcriptional inhibition of the human insulin receptor gene by aldosterone. J Steroid Biochem Mol Biol 2003, 84:543–553.CrossRefPubMed

41.

• Wada T, Ohshima S, Fujisawa E, et al.: Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3 T3-L1 adipocytes. Endocrinology 2009, 150:1662–1669. Aldosterone treatment in the adipocyte cell line resulted in IRS-1 serine phosphorylation and degradation, leading to decreased insulin stimulation of both Akt activation and glucose uptake. This mechanism was suggested to involve aldosterone-mediated intracellular oxidative stress.CrossRefPubMed

42.

Sato A, Fukuda S: Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. J Hum Hypertens 2009 Oct 29 (Epub ahead of print).

43.

• Wada T, Kenmochi H, Miyashita Y, et al.: Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 2010, 151:2040–2049. MR blockade improved glucose metabolism (assessed by the glucose tolerance test and insulin tolerance test), reduced triglyceride and cholesterol levels, reduced hepatic inflammation (decreased hepatic expression of TNFα, interleukin-6, and MCP-1), and reduced hepatic steatosis in mice fed a high-fat and high-fructose diet.CrossRefPubMed

44.

Kirilmaz B, Asgun F, Alioglu E, et al.: High inflammatory activity related to the number of metabolic syndrome components. J Clin Hypertens (Greenwich) 2010, 12:136–144.CrossRef

45.

Caprio M, Newfell BG, la Sala A, et al.: Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 2008, 102:1359–1367.CrossRefPubMed

46.

•• Limor R, Kaplan M, Sharon O, et al.: Aldosterone up-regulates 12- and 15-lipoxygenase expression and LDL oxidation in human vascular smooth muscle cells. J Cell Biochem 2009, 108:1203–1210. Treating vascular smooth muscle cells with aldosterone resulted in increased expression of 12- and 15-lipoxygenase expression and increased LDL oxidation. These effects were blocked by MR antagonists or an EGF-receptor antagonist, demonstrating potential interactions between these two receptors.CrossRefPubMed

47.

Joffe HV, Kwong RY, Gerhard-Herman MD, et al.: Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 2007, 92:2552–2558.CrossRefPubMed

48.

Izawa H, Murohara T, Nagata K, et al.: Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 2005, 112:2940–2945.PubMed

49.

Grandi AM, Imperiale D, Santillo R, et al.: Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 2002, 40:647–652.CrossRefPubMed

50.

• The NAVIGATOR Study Group: Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 363:1477–1490. In this large, placebo-controlled, randomized trial among patients with impaired glucose tolerance (many of whom met the MetS diagnostic criteria), the use of valsartan for 5 years led to a relative reduction of 14% in the incidence of diabetes. This study supports a role for blockade of the RAAS in preventing progression to diabetes.CrossRef

Titel: Mineralocorticoid Receptor Antagonists and the Metabolic Syndrome
verfasst von: Amir Tirosh
Rajesh Garg
Gail K. Adler
Publikationsdatum: 01.08.2010
Verlag: Current Science Inc.
Erschienen in: Current Hypertension Reports / Ausgabe 4/2010
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-010-0126-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Mineralocorticoid Receptor Antagonists and the Metabolic Syndrome

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

Drug Mechanisms to Help in Managing Resistant Hypertension in Obesity

Do the Blood Pressure Effects of Nonsteroidal Antiinflammatory Drugs Influence Cardiovascular Morbidity and Mortality?

Polypill: Lights and Shadows

The “J Curve” Problem Revisited: Old and New Findings

ESCAPE: From Hypertension to Renal Failure

Inflammation and Therapy for Hypertension

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin